Ann: Annual Report to shareholders, page-8

Whilst some may regard patience as a virtue, it's hardly a recommended strategy with pump and dump stocks.

This stock has some excellent short-term catalysts, and a leader who astutely explores multiple opportunities and is strongly focused on minimising time-to-commercialisation. However, there are questions around the solidity of its IP.

Off-setting that short-term volatile risk-reward mix is the longer-term pipeline of non-oncology prospects held through Nyrada.

I think you're confusing pump and dump (puff pieces with no real progress to report) with an actively managed biotech that frequently has new developments or significant interim trial data to report.